SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
June 17, 2024 09:05 ET
|
SELLAS Life Sciences Group, Inc.
– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications – – No Safety or Futility Concerns Were Raised Based on the Efficacy...
Great American Cookies Has a Zest for Summer with All-New Lemon Cookie
June 17, 2024 09:00 ET
|
FAT Brands Inc.
Lemon Cookie, Blueberry Muffin Cookie and Strawberry Crinkle Cookie Make for Picnic Perfect Pairing LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Great American Cookies, the Original Cookie Cake...
LPL Financial Welcomes Russell Wealth Partners
June 17, 2024 09:00 ET
|
LPL Financial Holdings, Inc.
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (Nasdaq: LPLA) announced today that financial advisor Tom Russell, CFP®, and his sons Brian Russell and Charles Russell have joined...
Shineco Enters into an Agreement with Turing Video to Jointly Develop Intelligent Health Care Products
June 17, 2024 09:00 ET
|
Shineco, Inc.
Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today...
NVIDIA Announces Omniverse Microservices to Supercharge Physical AI
June 17, 2024 09:00 ET
|
NVIDIA
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- CVPR—NVIDIA today announced NVIDIA Omniverse Cloud Sensor RTX™, a set of microservices that enable physically accurate sensor simulation to accelerate the...
iTeos und GSK starten Phase-III-Studie GALAXIES Lung-301 zur Untersuchung von Belrestotug und Dostarlimab bei zuvor unbehandeltem, inoperablem, lokal fortgeschrittenem/metastasiertem, PD-L1-selektiertem, nicht-kleinzelligem Lungenkrebs
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Massachusetts, und GOSSELIES, Belgien, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) („iTeos“), ein im klinischen Stadium tätiges Biopharmazie-Unternehmen, das...
Début de l’étude GALAXIES Lung-301 de Phase III à l’initiative conjointe d’iTeos et de GSK, visant à évaluer le doublet belrestotug + dostarlimab chez les patients atteints d’un cancer du poumon non à petites cellules PD-L1-positif, localement avancé ou métastatique, non résécable, non préalablement traité
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, État du Massachusetts et GOSSELIES, Belgique, 17 juin 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), ci-après « iTeos », une société biopharmaceutique au stade...
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
PodcastOne (Nasdaq: PODC) Adds Tactful Pettiness Podcast to Its Network
June 17, 2024 09:00 ET
|
PodcastOne
- Hosted by Cody Rigsby and Andrew Chappelle - 8th New Podcast Joining PodcastOne Network This Fiscal Year, 39th In Last 12 Months - Total of 184 Shows on the PodcastOne Network - Combined Social...
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...